REQUEST A DEMO
Total
USD $0.00
Search more companies

Anya Biopharm Inc. (Taiwan, China)

Main Activities: Research and Development in Nanotechnology
Full name: Anya Biopharm Inc. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

Anya is a young, agile and innovative publicly listed (TWO: 7776) pharmaceutical company founded in Taipei, Taiwan with offices in India and the United States. Our core mission is to be the authority in oral delivery of peptides. Our patented technology platform Mira/Je® is a flexible solution easy to adapt to a large variety of peptides. Mira/Je® has shown delivery of therapeutic amount in a number of clinical and preclinical studies in a variety of peptides such as teriparatide, leuprorelin, octreotide, semaglutide, liraglutide, tirzepatide and insulin glargine.

Headquarters
4F., No. 3-2, Yuanqu St., Nangang Dist
Taipei City; Taipei City;

Contact Details: Purchase the Anya Biopharm Inc. report to view the information.

Website: http://anyabiopharm.com/tw/

Basic Information
Outstanding Shares:
Purchase the Anya Biopharm Inc. report to view the information.
Financial Auditors:
Purchase the Anya Biopharm Inc. report to view the information.
Incorporation Date:
December 08, 2025
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Financial Officer
Subsidiaries
Anya Biopharm India Llp (India)
99%
Company Performance
Financial values in the chart are available after Anya Biopharm Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
462.57%
Total operating revenue
460.17%
Operating profit (EBIT)
0.02%
EBITDA
0.84%
Net Profit (Loss) for the Period
-127%
Total assets
-18.17%
Total equity
-15.86%
Operating Profit Margin (ROS)
3406.8%
Net Profit Margin
2563.86%
Return on Equity (ROE)
-10.79%
Debt to Equity Ratio
-0.1%
Quick Ratio
20.2%
Cash Ratio
5.79%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?